Moreover, K-Ras mutations specifically G12C mutations are prevalent in colon, pancreatic and lung cancers, so targeting K-Ras has a promising potential in ending the undruggable era of Ras protein [8]. This evidence concerns the gene KRAS and lung carcinoma.